Background: Thoracic endovascular aortic repair (TEVAR) has become an alternative to open repair for the treatment of ruptured thoracic aortic aneurysms (rTAAs). The aim of this study was to assess national trends in the use of TEVAR for the treatment of rTAA and to determine its impact on perioperative outcomes.
A ruptured descending thoracic aortic aneurysm (rTAA) is a life-threatening diagnosis, with an estimated mortality exceeding 90%. 1 The majority of patients die before making it to the emergency department. For those hemodynamically stable enough to reach the hospital and to undergo surgery, 1 traditional open repair requires an emergency thoracotomy to replace the diseased aorta with an interposition graft. Despite the fact that hospitalized patients are presumed to have a better prognosis, mortality after surgery is as high as 45%, 2, 3 with surviving patients often suffering disabling complications, such as paraplegia and stroke. 2, [4] [5] [6] As a minimally invasive alternative, thoracic endovascular aortic repair (TEVAR) for rTAA was first introduced and described by Semba et al in 1997. 7, 8 In subsequent years, single-institution studies were performed to evaluate its feasibility and performance compared with conventional open repair. 4, [9] [10] [11] [12] [13] [14] Although some of these studies showed encouraging perioperative results favoring TEVAR, they were often limited by small numbers and the inclusion of other acute aortic diseases. Moreover, an absolute perioperative survival benefit of TEVAR over open repair could not be confirmed. 4, 14 Reports on outcome of rTAA using early national data from the National Inpatient Sample (NIS) yielded conflicting results, despite the same cohort of TEVAR patients.
Previous studies have demonstrated that for patients presenting with a traumatic thoracic aortic injury, the introduction of TEVAR has reduced the proportion of patients managed nonoperatively. 15, 16 For rTAA patients, however, it is unknown whether the introduction of TEVAR has broadened their treatment eligibility. 15 The purpose of this study was to assess national trends in the treatment of rTAA, focusing on the relative use and outcome of TEVAR, open repair, and nonoperative treatment.
METHODS
For this study, we used the NIS. The NIS is the largest U.S. all-payer inpatient database; it is maintained by the Agency for Healthcare Research and Quality as part of the Healthcare Cost and Utilization Project. From the U.S. states participating in the Healthcare Cost and Utilization Project, which represent 96% of the U.S. population in more recent years, a 20% stratified sample of hospitals is selected to accurately represent hospital admissions nationally. 17 Actual annual U.S. hospitalization volumes are approximated using hospital sampling weights. The weighted estimates are used for all analyses in this study, as recommended by the Agency for Healthcare Research and Quality. The Institutional Review Board of Beth Israel Deaconess Medical Center approved this study, and consent of the patient was waived because of the deidentified nature of the data. Patients were identified using International Classification of Diseases, Ninth Revision codes. All patients admitted with an rTAA (411.1) were identified. Patients were subsequently divided into the open repair group (38.35) and the TEVAR group (39.73). Those with a primary diagnosis of a ruptured aneurysm without mention of any procedure were considered nonoperatively treated. In an effort to capture TEVAR cases before TEVAR procedure coding was introduced in 2005, patients with a primary diagnosis of an rTAA in combination with mention of endovascular aneurysm repair (39.71) or insertion of non-drug-eluting peripheral (noncoronary) vessel stent (39.90) were also considered to have undergone endovascular repair. Patients with a procedure code for both open repair and TEVAR were excluded. In addition, those with a concomitant diagnosis for thoracoabdominal aneurysm (diagnosis codes 441.3 to 441.9 or procedure codes 38.44 and 39.71), aortic dissection (diagnosis codes 441.00 to 441.03), or connective tissue disorder (diagnosis codes 446.0-446.7, 758.6, and 759.82) were excluded from this study. To separate ascending from descending aneurysms, patients with procedure codes for cardioplegia (39.63), valve surgery (35.00-35.99), and procedures on the vessels of the heart (36.00-36.99, 37.0, 37.2, 37.31-37.90, 37.93, and 37.99) were also excluded as they are more likely to represent aneurysms of the ascending aorta. We compared patient demographics (age, gender, race) and comorbid conditions (coronary artery disease, diabetes, hypertension, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and cerebrovascular disease). We additionally assessed differences in hospital characteristics, including hospital bed size (small, medium, large), setting, and teaching status (rural, urban nonteaching, urban teaching). Hospital bed size category varies according to location and teaching status. Small hospital bed size is defined as 1 to 49, 50 to 99, and 1 to 299 beds, respectively, for rural, urban nonteaching, and urban teaching hospitals; medium bed size is defined as 50 to 99, 100 to 199, and 300 to 499, respectively; and a large bed size hospital is considered 100þ, 200þ, and 500þ beds, respectively. Adverse in-hospital outcomes included death, cardiac or respiratory complications, paraplegia, stroke, acute renal failure, wound dehiscence, and infection. Cardiac complications included postoperative myocardial infarction, cardiac arrest, cardiogenic shock, and ventricular fibrillation (Supplementary Table, appropriate. Trend analyses were performed using the Cochran-Armitage test for trend. To assess the independent risk associated with treatment options for rTAA, we subsequently performed multivariable logistic regression analysis. Predictors with a P < .1 were entered into the multivariable model. Because of the limited number of diagnoses that can be provided per patient in this data set, less life-threatening comorbid conditions are under-reported in more complex cases. Because these conditions act as confounders for less severe cases, we chose not to include comorbidities with protective risk estimates on the univariate screening in the multivariable model. Comorbidities excluded as a result were diabetes, hypertension, and cerebrovascular disease. HosmerLemeshow goodness of fit testing was used to evaluate the multivariable model. All tests were two sided, and significance was considered when P < .05. Statistical analysis was performed using SPSS Statistics 21 (IBM Corp, Armonk, NY).
RESULTS
A total of 12,399 patients were included, with 1622 (13%) undergoing TEVAR, 2808 (23%) undergoing open repair, and 7969 (64%) not undergoing surgical treatment. Fig 1) . Concurrently, the proportion of patients undergoing open repair declined from 29% to 12% (P < .001). Despite a decrease in open repair, the overall proportion of patients undergoing surgical repair after rTAA admission dramatically increased once TEVAR received Food and Drug Administration approval in 2005 (31% to 55%; P < .001).
Although an increase in surgical repair was observed in all age groups, it was not uniform. The use of surgical treatment for patients younger than 70 years increased 207% from 1993-1994 to 2011-2012 (P < .001; Fig 2, A) . For those aged 70 to 80 years, this was 177% (P < .001). With a 750% increase during the study period, the shift toward operative management was most pronounced among those aged 80 years and older. Fig 2, B illustrates that the adoption of TEVAR started relatively early among the eldest patients, as 18% of patients aged 80 years and older were undergoing TEVAR before its Food and Drug Administration approval (<70 years, 3%; 70-80 years, 9%; P ¼ .004). In 2011-2012, only 14% of patients aged 80þ years underwent open repair, which was significantly lower compared with the <70-year age group (25%) and 70-to 80-year age group (24%; P ¼ .008). When population-adjusted trends were evaluated, an overall decrease in rTAA admissions was observed from 1993 to 2004 (4.7 to 3.6 per million; Fig 3) , a rate that stabilized thereafter. The number of patients surgically treated increased since 2003-2004 from 1.4 to 1.9 per million. This was observed among patients younger than 70 years (0.8 to 1.1 per million) but more strongly among patients aged 80 years and older (3.5 to 9.9 per million).
Baseline characteristics. Baseline characteristics are detailed in Table I . In comparing TEVAR patients with those undergoing open repair, we found that TEVAR patients were substantially older (72 years vs 66 years; P < .001). In terms of comorbidities, TEVAR patients more often had diabetes (14% vs 11%; P ¼ .031) and hypertension (75% vs 60%; P < .001). In addition, coronary artery disease (27% vs 18%; P < .001) and chronic kidney disease (21% vs 11%; P < .001) were more common among those undergoing TEVAR compared with open repair. TEVAR was more often performed in academic centers (85% vs 75%; P < .001) and larger bed size hospitals (82% vs 79%; Perioperative mortality. In-hospital mortality was significantly lower for patients undergoing TEVAR compared with open repair (22% vs 33%; P < .001; Table II) . After nonoperative treatment, in-hospital mortality was 60%. In adjusted analysis, open repair was associated with a twofold higher mortality compared with TEVAR (odds ratio, 2.0; 95% confidence interval, 1.7-2.5; Table III), whereas nonoperative management was associated with a fivefold increase in mortality (odds ratio, 5.0; 95% confidence interval, 4.3-5.9). From 2005 onward, mortality after TEVAR increased nonsignificantly from 21% to 26% (P ¼ .219; Fig 4) , whereas mortality after open repair decreased During that same time, overall procedural mortality decreased from 36% to 27% (P < .001), whereas mortality among those undergoing nonoperative treatment remained stable between 63% and 60% (P ¼ .167). As TEVAR became more widely adopteddand the proportion of patients undergoing nonoperative treatment decreaseddoverall mortality after rTAA admission decreased from 55% to 42% (P < .001).
Despite an increase in rTAA admissions among those younger than 70 years after the introduction of TEVAR, in-hospital deaths declined after 2003-2004 (0.6 to 0.4 per million; Fig 3) . Similarly, for those older than 80 years, death after rTAA admission declined (16.7 to 13.3 per million), even though the rTAA admission incidence increased. The population-adjusted incidence of death after rTAA in patients 70 to 80 years of age also decreased considerably (7.1 to 3.0 per million), although this was concurrent with a strong decline in admission for rTAA. Similar declining trends were seen in the national WONDER data from the Centers for Disease Control and Prevention, with rTAA mortality declining from 1.0 to 0. Perioperative complications. In addition to favorable mortality, TEVAR was associated with a lower incidence of cardiac complications (17% vs 31%; P < .001), paraplegia (4% vs 6%; P ¼ .031), respiratory complications (33% vs 43%; P < .001), wound dehiscence (0.9% vs 4%; P < .001), postoperative infection (0.6% vs 4%; P < .001), and bleeding complications (14% vs 18%; P ¼ .015) compared with open repair. In addition, those undergoing TEVAR had a significantly shorter hospital stay (14 days vs 17 days; P < .001) and were more likely to be discharged to home (27% vs 21%; P ¼ .002).
DISCUSSION
This study demonstrates that since its introduction, endovascular repair has rapidly increased in use for the treatment of rTAA and is currently the primary mode of treatment. Aside from replacing open repair, TEVAR has led to an increase in the proportion of rTAA patients being treated surgically, particularly among patients older than 80 years. As a result, the majority of patients admitted for rTAA now undergo surgical repair. TEVAR was associated with favorable outcomes compared with open repair, despite TEVAR patients being older and having more comorbidities. Because of the shift from open repair to TEVAR and the shift from nonoperative treatment to TEVAR, overall mortality after rTAA admission declined during the study period.
The feasibility of endovascular repair in an acute setting for rTAA was first described in 1997. 7 In 2004, Scheinert et al reported a 30-day mortality of 9.7% among a cohort of 31 rTAA patients. 10 Other series reported similar encouraging results, with mortality ranging between 3.1% and 24.6%. Comparing these outcomes to historic results for open repair with mortality of up to 45%, 2, 6 Mitchell et al concluded that TEVAR has become the treatment of choice for acute thoracic aortic surgical emergencies. 13 However, comparative studies were unable to establish an absolute survival benefit of TEVAR over open repair. 4, 11, 14 Jonker et al evaluated morbidity and mortality after both operative approaches and demonstrated that TEVAR was associated with a lower rate of perioperative adverse events in a multiinstitutional study. Mortality, however, was not significantly reduced in TEVAR patients. 4 These findings were supported by Patel et al, who also demonstrated a lower incidence of adverse events in a composite outcome measure.
14 When Gopaldas et al used the NIS in an effort to assess rTAA outcomes on a national level for the years in which both treatments were available (2006) (2007) (2008) , neither mortality nor complication rates differed between TEVAR and open repair. 19 Conversely, a recent study also using NIS data up until 2008 found that TEVAR was associated with a reduction in perioperative mortality compared with open repair. 20 In this study, however, open repairs as far back as 1998 were compared with TEVAR patients treated in 2008, which resulted in substantially higher in-hospital mortality after open repair of 53% compared with 29% in the Gopaldas study. In the present study using more recent data, we limited comparative analysis to data after the introduction of TEVAR. In contrast to Gopaldas et al, we found that perioperative morbidity and mortality after TEVAR were significantly lower compared with open repair. This difference is most likely due to the fact that the present Our study, similar to previous studies using the NIS, is unable to assess long-term follow-up. However, previous reports have shown equivalent survival at 1 year and 5 years despite a substantially lower perioperative mortality after TEVAR. [21] [22] [23] Patel et al had similar 5-year findings in a cohort of 69 rTAA patients, although no significant differences in survival were observed in the perioperative period either. 14 Mortality among patients undergoing nonoperative treatment was lower than expected, which is similar to previous studies using national registries for the identification of acute aortic diseases. 15 In our study, mortality among the nonoperative treatment group was approximately 60%, which is considerably lower compared with previous studies reporting rates This suggests the decrease in rTAA mortality through increased eligibility for surgery to be even greater than demonstrated in the present study. Whereas increases in the proportion of patients undergoing surgery were observed in all age groups, treatment changed most significantly among patients aged 80 years and older after the introduction of TEVAR, with surgical treatment increasing by a factor of three since [2003] [2004] . This is similar to the increase in operative treatment among elderly patients with abdominal aortic aneurysm (AAA) observed after the introduction of endovascular repair for AAA. 24 These trends were also apparent after population adjustment, with substantial increases in the number of surgical interventions per million and a concurrent decline in in-hospital death. 24, 27 In this study, Fig 3 illustrates that for rTAA, the decline in admissions and deaths started before the introduction of TEVAR. Nevertheless, the prevention of rupture through increased elective repair may very well have contributed to the decline in ruptures and deaths in patients with TAA in the period thereafter. Other contributing factors may be the increased focus on familial screening programs and improved cardiovascular risk factor modification, including the decline in smoking in the United States during the last decades. 28, 29 Similar to previous studies assessing the role of endovascular repair, we found that TEVAR was more commonly performed in urban teaching hospitals. 16, 30, 31 This was expected, as novel technologies and techniques such as TEVAR are typically introduced first to high-volume academic centers. This study has several limitations that should be addressed. First, since the NIS is an International Classification of Diseases, Ninth Revision-based database, it does not provide detailed operative or clinical data, including hemodynamic status at admission, time to surgery, and the use of conduits. Consequently, we are unable to assess the role of hemodynamics on operative selection or to establish the clinical implications of various patient and operative factors. Anatomic data are also lacking, which may have an impact on the choice of open repair vs TEVAR and may also affect outcome. In addition, previous studies have indicated that evaluation of surgical complications from administrative databases should be interpreted with caution because documentation of nonfatal perioperative outcomes may be troubled. [32] [33] [34] Because some complications may have been documented as comorbid conditions, these baseline characteristics could interfere with the adjusted analysis. Therefore, the multivariable model was tested without the inclusion of myocardial infarction and heart failure. No notable changes were observed with regard to the adjusted difference in mortality between TEVAR and open repair. Furthermore, only a limited number of diagnoses can be reported per patient. As a result, common comorbidities may be under-reported in the sickest patients, leading to confounding for less severe cases. Because these protective risk estimates do not accurately reflect the association with mortality, we decided to exclude these variables from further analyses. Although the exclusion avoided unwanted interference with the outcomes, the underreporting of these comorbidities precluded purposeful selection as a means for constructing the multivariable model.
CONCLUSIONS
This study shows that TEVAR has been increasingly used since its introduction and appears to be associated with significantly lower perioperative morbidity and mortality than traditional open surgical repair. In addition to replacing open repair as the dominant surgical approach for rTAA nationally, TEVAR has broadened treatment eligibility, with the majority of patients presenting with rTAA now undergoing operative intervention. As a result of the shift from open repair and nonoperative treatment to TEVAR, overall in-hospital mortality after rTAA admission has decreased in recent years. 
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